Last Updated: June 7, 2026 at 10:18 a.m. ET
First Published: June 6, 2026 at 2:53 p.m. ET
One of the most anticipated new weight-loss drugs also helped people struggling with common obesity-related conditions like sleep apnea.
The drug is retatrutide, which pairs GLP-1, GIP and glucagon in a powerful combination that produces more weight loss than any other therapy. It’s currently in Phase 3 trials, and Wall Street expects Eli Lilly’s LLY once-weekly drug to launch in the U.S. next year if it’s approved by the Food and Drug Administration.